You're using a free limited version of DrugPatentWatch: Upgrade for Complete Access

Last Updated: November 22, 2024

Litigation Details for OTSUKA PHARMACEUTICAL CO., LTD. v. TORRENT PHARMACEUTICALS LIMITED (D.N.J. 2014)

✉ Email this page to a colleague

« Back to Dashboard

OTSUKA PHARMACEUTICAL CO., LTD. v. TORRENT PHARMACEUTICALS LIMITED (D.N.J. 2014)

Docket	⤷ Sign Up	Date Filed	2014-02-18
Court	District Court, D. New Jersey	Date Terminated	2017-09-29
Cause	35:271 Patent Infringement	Assigned To	Jerome B. Simandle
Jury Demand		Referred To	Karen M. Williams
Patents	7,053,092; 8,017,615; 8,580,796; 8,642,600; 8,642,760; 8,759,350
Link to Docket	External link to docket

Small Molecule Drugs cited in OTSUKA PHARMACEUTICAL CO., LTD. v. TORRENT PHARMACEUTICALS LIMITED

The small molecule drugs covered by the patents cited in this case are ⤷ Sign Up and ⤷ Sign Up .

Details for OTSUKA PHARMACEUTICAL CO., LTD. v. TORRENT PHARMACEUTICALS LIMITED (D.N.J. 2014)

+ Get email alerts for changes to this table

Subscribe to access the full database, or Sign Up
Date Filed	Document No.	Description	Snippet	Link To Document
0000-00-00				External link to document
0000-00-00	127	Opinion	various patents covering Otsuka’s Abilify® aripiprazole product, U.S. Patent Nos. 8,017,615 (“the ’…primary compound patent for Abilify, U.S. Patent No. 5,006,528 (hereinafter, the “’528 Patent”), and because… ’615 patent”) and 8,580,796 (“the ’796 patent”). Otsuka now moves to dismiss Torrent’s Fifth…for trial the patent issues raised in this litigation from the antitrust and/or patent misuse issues… 355(j), Otsuka identifies the ’615 patent and the ’796 patent, both of which Otsuka owns by virtue	External link to document
2015-09-25	152	Memorandum	include: U.S. Patent Nos. 5,006,528 (“the ’528 patent”), 7,053,092 (“the ’092 patent”), 8,017,615 (… (“the ’615 patent”), 8,580,796 (“the ’796 patent”), 8,642,600 (“the ’600 patent”), 8,642,760 (“the…the ’760 patent”), and 8,759,350 (“the ’350 patent,” and collectively, the “patents-in-suit”). …various patents covering Otsuka’s brand name aripiprazole product, Abilify®. 1 1 The patents asserted…Local Patent Rules, the Court explains at the outset the overall structure of the Local Patent Rules	External link to document
2015-11-15	166	Opinion	5,006,528 (“the ’528 patent”), 7,053,092 (“the ’092 patent”), 8,017,615 (“the ’615 patent”), 8,580,796 (“…(“the ’796 patent”), 8,642,600 (“the ’600 patent”), 8,642,760 (“the ’760 patent”), and 8,759,350…identifies the ’528 Patent, the primary aripiprazole compound patent, as well the ’600 Patent, which claims…The ’350 Patent: Otsuka’s Asserted Method of Use Patent The ’350 Patent, by contrast…specifications: 23 (See ’615 Patent at 9:36-63; ’760 Patent at 9:37-63; ’796 Patent at 9:34-60.) 23Although	External link to document
>Date Filed	>Document No.	>Description	>Snippet	>Link To Document

Make Better Decisions: Try a trial or see plans & pricing

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.